{
  "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
  "chunks": [
    {
      "text": "Sotorasib OPINION ON THE",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "EVALUATION OF HEALTH TECHNOLOGIES",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung cancer - Adult - Sectors: City and Hospital Notice to maintain reimbursement \"in monotherapy in the treatment of adult patients with advanced non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line\" Place in LUMYKRAS (sotorasib) is an option for treatment in the management of adult patients with advanced rautical non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Adopted by the Commission on Transparency on 19 July 2023",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Improvement No progress compared to the medical service docetaxel rendered (ASMR) LUMYRAS (sotorasib) showed statistically significant superiority in terms of progression-free survival and objective response rate evaluated by an independent review committee in an open-label Phase 3 study compared to docetaxel. However, this result is limited by: - the lack of clinical relevance of the absolute difference in progression-free survival medians, about 1 month; - the open-label conduct of the study, resulting in pos-ible evaluation biases, particularly in terms of treatment decisions; - the uncertain reproducibility of progression-free survival measurement in this study;",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "(PSI)",
        "start_page": 1,
        "end_page": 2,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Commission considers that LUMYKRAS (sotorasib) does not improve the medical service rendered (ASMR V) in relation to docetaxel.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Target",
        "start_page": 2,
        "end_page": 2,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "S",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "The target population is estimated at about 1950 patients.",
        "start_page": 3,
        "end_page": 3,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Background Medical environment General of the disease or condition concerned Current management Coverage of the medical need Synthesis of the data Available data Synthesis of the efficacy data 3.2.1 Reminders of the clinical data previously examined by the Commission of 15/06/2022): study CodeBreak 100 (non-comparative basketball study) 3.2.2 New efficacy data provided in support of this re-evaluation: study CodeBreak 200 Tolerance profile 3.3.1 Recalls of the clinical data previously examined by the Commission of 15/06/2022): study CodeBreak 100 (non-comparative basketball study) 3.3.2 New safety data provided in support of this re-evaluation Use data 3.4.1 Cohort ATU 3.4.2 1st report of early access post-AML 3.4.3 Observatory study IFCT-2102 Lung KG12Ci Study programme Discussion Findings of the Commission of the Transparency Clinically relevant comparators Service Medical Rendu Improvement of the Medical Service Target population Data request Other recommendations of the Commission This document and its bibliographical reference are available for download only Abortion of this information Abortion of the Commission of the Council of the Commission of the of of of the of the of of of of the of of of agglomeration agglomeration agitation agglomeration agitation agglomeration agglomeration agglomeration agitation agglomeration agitation agitation ag ag ang ag ag a Authorization for early access post-AMM (date granted on 28/04/2022, starting date on 07/06/2022) in the following indication, identical to that of the MAH: \"as monotherapy in the treatment of adult patients with advanced non-small cell bronchial can- cer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.\" Posology in For further clarification, refer to the SPC. evaluative indication Pharmaco--This is a selective inhibitor of the KRAS G12C protein.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Contents",
        "start_page": 3,
        "end_page": 5,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Information at ni- Management in Germany, Austria, Bulgaria, Slovenia and Sweden in the international calf* indication of the AMM. Management under evaluation in Belgium, Spain, Italy and the Netherlands. Management in the United Kingdom in the indication: \"LUMYKRAS is indicated as monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy\" AMM in the United States superimposed or metastatic non-small cell cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti-PD/PD-L1 immunotherapy\" AMM in the U.S.A.B.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D.D",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Therapeutics",
        "start_page": 5,
        "end_page": 5,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Bronchial cancer is the 2nd most common cancer in men and the 3rd most common in women among solid tumours (more than 46,000 new cases per year in 2018). The median age of diagnosis is 67 years with a majority of diagnoses (70 to 80%) carried out in locally advanced or metastatic stages. With 33 117 deaths estimated in 2018, bronchial cancer is also ranked first among cancer deaths in men and second among women. Non-small cell bronchial cancer (NCCB) accounts for almost 85% of all lung cancers.1 The prevalence of KRAS G12C mutation in CBNPC has been estimated at approximately 14%1.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "General information on the disease or disease concerned",
        "start_page": 5,
        "end_page": 6,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Prior to the provision of LUMYKRAS (sotorasib), there was no specific treatment targeting the KRAS G12C mutation. The current therapeutic management is identical, whether or not patients have a KRAS mutation (including G12C).1 In the initial assessment of LUMYKRAS (sotorasib), the Transparency Commission had considered that, given the prognostic and predictive value currently poorly established of the KRAS G12C mutation, and the absence of comparative data of acceptable methodological quality, its place vis-à-vis therapeutic alternatives (chemiotherapy and immunotherapy) could not be specified. The management of patients with advanced CBNPC, whose disease has progressed after at least one previous treatment line (immunotherapy ± chemotherapy only), is based on a metastatic stage (IV) apart from cancers with additive mutation, it is recommended to propose a second-line treatment, whether or not patients have responded to a 1st metastatic line.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Current support",
        "start_page": 6,
        "end_page": 6,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "- LUMYKRAS (sotorasib) is a treatment option in the management of patients with advanced KRAS G12C mutation after at least one previous systemic treatment line;",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Current support",
        "start_page": 6,
        "end_page": 6,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Table 1: List of drug treatments with MMA in the assessment perimeter NAME (INN) MMA indication Date of MRS ASMR Laboratoire l'avis Chimitherapies Generics of advanced or metastasé CBNPC NA & NA & NA cisplatin Accord, Teva, Via- tris 1 TB Notice of 15/06/2022 – LUMYKRAS – 19740_LUMYKRAS_PIC_INS_NoticeDef_CT19740.pdf CBNPC Generics NA & carboplatin Accord, Arrow, Hospira, Kabi, Teva, Viatris NAVELBINE CBNPC NA & (vinorelbine) Pierre Fabre et ge-nériques: Accord, Arrow, Sandoz TAXOL In combination with cisplatin, in the NA & CBNPC for which a po- (paclitaxel) therapeutically curative surgery and/or a radio- Bristol-Myers therapy n & N is not indicated for the same time, not for the same time, and not for the same time.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Medicated treatments",
        "start_page": 6,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "TECENTRIQ monotherapy in local CBNPC (advanced or metastatic) (inscribed (atezolizumab) anterior chemotherapy Roche OPDIVO CBNPC epidermoid locally 03/02/ advanced or metastatic after (inscribed (nivolumab) anterior chemotherapy Bristol-Myers Squibb CBNPC non-epidermoid locally 11/01/ advanced or metastatic after (inscribed chemotherapy KEYTRUDA CBNPC locally advanced or metas- 03/03/ tatique, with PD-L1 ≥ 1%, and having (reeva (pembolizumab) received at least one chemotherapy an-mentor MSD tablet",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Immunotherapy",
        "start_page": 7,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Despite these treatments, the prognosis of advanced CBNPC is dark, with overall survival at 5 years ranging from 15% to 50% in patients eligible for targeted therapies or immunotherapy.1 The medical need is therefore currently partially covered by the alternatives available. However, there is still a medical need to have medicines that improve the overall survival and quality of life of these patients.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Coverage of medical need",
        "start_page": 8,
        "end_page": 8,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The initial review of LUMYKRAS (sotorasib) was based primarily on a phase 1/2 basketball (CodeBreak 100) non-comparative study in 224 patients, 126 of whom had NSCLC, and whose main objective was to estimate the objective response rate, assessed by an independent review committee. The main results of this study already examined in the opinion of 15/06/2022 will be recalled below. The laboratory had also submitted: - the data from an indirect comparison (CodeBreak 100 versus ESME cohort). However, given the large number of missing data, no formal conclusions could be drawn from this study. Since the results of this analysis were not presented in the initial opinion, they will also not be described in this re-evaluation. - the data from the 1st synthesis report of the ATU. However, given the large number of missing data, no formal conclusions could be drawn from this analysis in terms of sufficient curability or tolerance.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Data available",
        "start_page": 8,
        "end_page": 8,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "3.2.1 Aggregated recall of clinical data previously examined by the Commission (opinion of 15/06/2022): CodeBreak study 100 (non-comparative basketball study) \"A total of 126 patients with NSCLC were included. Median age was 64 years, with a similar proportion of males/females (50%) and patients in good general condition, with an ECOG stage of 0 (30%) or 1 (70%). Almost all patients had metastatic (96%) and a non-epidermoid tumour (99%). A total of 43% of patients had received only one year-old line, 35% two lines and 22% had received three previous lines. The main analysis was f-fected on 123 patients (data of 01 September 2020), with a total of 909 patients (data of 01 September 2020), corresponding to the full analyssis set, because 3 patients were considered to have received only one single year-old line, 35% two lines and 22% had received three previous lines. Prior treatment must include platinum-based chemotherapy and immunotherapy (whether given concomitantly or successively), unless contraindicated.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Synthesis of efficacy data",
        "start_page": 8,
        "end_page": 9,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patients were randomized (allocation ratio 1:1) to receive: - Experimental group: sotorasib, 960 mg/day, oral route; - Control group: docetaxel, 75mg/m2 every 3 weeks, route IV (MMA posology); Randomization was stratified according to the following criteria: number of previous lines (1 vs. 2 vs. 3 and +), geographical origin (Asian versus non-Asian) and CNS (present vs. absent).",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Treatment received",
        "start_page": 9,
        "end_page": 9,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The primary assessment criterion was progression-free survival evaluated by an independent blind review committee. Progress-free survival was defined as the time between randomization and progression according to the RECIST criteria 1.1, or all-cause death. Note that patients who started a new cancer treatment prior to progression or death were censored at the date of last assessment prior to initiation. A sensitivity analysis was performed by considering these initiations as progression-free survival events. Note that in the event of death or progression immediately after missing at least two evaluations, patients were censored at the date of last assessment without progression or death.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Criteria for judgement",
        "start_page": 9,
        "end_page": 10,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "No sensitivity analysis was performed on this point. The following judgement criteria were controlled for the multiplicity of tests (monitorous alpha risk control at 0.025) using the Maurer-Bretz procedure: - Progress-free survival evaluated by the independent review committee, blind (primary criterion, cf. above) The following judgement criteria were controlled for the multiplicity of tests (monitorial alpha risk control at 0.025) using the Maurer-Bretz procedure. The following intermediate analyses were planned a priori: - An intermediate analysis of progression-free survival was planned after the occurrence of 160 events or if recruitment was completed and all patients followed for at least 6 weeks. The final progression-free survival analysis was planned after the occurrence of 230 events; - An intermediate analysis of overall survival was planned during the statistical significance of the effect on progression-free survival or after 175 deaths.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Criteria for judgement",
        "start_page": 9,
        "end_page": 10,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The final overall survival analysis was planned after the occurrence of 198 deaths; - Thresholds for these analyses were determined using the O-Brien-Fleming method for progression-free survival, and with a threshold of 0.01% for the intermediate analysis of overall survival.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Criteria for judgement",
        "start_page": 9,
        "end_page": 10,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "In Amendment 3 to the Protocol of 15/02/21 (1st randomisation carried out on 04/06/2020), several modifications were made: - Reduction of the number of subjects from 650 to 330 patients; - Addition of an intermediate analysis of progression-free survival (160 events); - Crossover possible for patients in the docetaxel group, in case of progression according to the Inves-tigator and confirmed by the independent committee.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Main amendments to the Protocol",
        "start_page": 10,
        "end_page": 10,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this open-label study, 2 patients in the LUMYKRAS group (sotorasib) and 23 patients in the docetaxel group did not receive the treatment. Note that 16 patients in the docetaxel group (sotorasib) and 174 patients in the docetaxel group (sotorasib) had not received the treatment. Results on the main judgment criterion: progression-free survival Intermediate analysis The protocol-predicted interim analysis was performed on the data freeze of 05/10/2021, after the occurrence of 171 events. The significance threshold (the O-method) for this interim analysis was 0.009, and for the final analysis of 0.022. The follow-up median was 30 weeks (min-max: 0-57) in the sotorasib group and 22 weeks (min-max: 0-56) in the docetaxel group. On the initial report of 20/12/2021, based on the data freeze of 05/10/2021, no significant differences were identified between the two groups: HR=0.8 [IC95%: 0.6-1.1].",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Study population",
        "start_page": 10,
        "end_page": 13,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The data follow-up committee recommended a continuation of the study without change. In April 2022, an updated analysis was performed on the same data of 05/10/2021. This update included a new evaluation of the events by the non-reformated test panel, including that of the non-reformated test, the non-reformified test was performed. Several methodological limitations are to be noted regarding this updated analysis, including: - the involvement of non-pre-specified evaluators, whose qualification and blindness were pre-defined (including a \"medical director\" of a CRO who participated in one of the stages of seduction of the discordant cases to be re-evaluated); - only the conclusions of the independent review committee were modified: the analysis by the centralized confirmation committee of the 1st progression was considered \"fair\", without any justification to support this hypothesis; - the failure to take into account the multiplicity of analyses related to this re-evaluation; in total, the reproducibility of the measure of progression-free survival in this trial can be questioned: the final analysis by the centralized confirmation committee of the 1st progression was considered \"fair\", without any justification to support this hypothesis; - the failure to take into account the multiplicity of analyses related to this re-evaluation; - the reproducibility of the measure of progression-free survival in this trial; - the reproducibility of the group without progression; - the final analysis of the survival without progression was carried out on the data freeze of the 02/08/2022 data in the 23 events; - the occurrences correspond to 168 progression (100 in the number of the number Figure 1: Progression-free survival curve evaluated by an independent committee according to the RECIST 1.1 criteria of the CodeBreak 200 study, final analysis Results on secondary endpoints with risk management alpha Objective response rate evaluated by an independent review committee according to the RECIST criteria In accordance with the statistical analysis plan, the statistical significance of progression-free survival (primary criterion) has been demonstrated, the statistical significance of the objective response rate has been tested. At 02/08/2022, the evaluation of the objective response was not feasible for 42 patients (24%) in the docetaxel group, and 10 patients (6%) in the sotorasib group, the statistical significance of the objective response rate has been tested.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Study population",
        "start_page": 10,
        "end_page": 13,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "At 02/08/2022, the evaluation of the objective response was not feasible for the overall response of the docetaxel group, the overall response of the doctaxel group, and 10 patients (6%) in the sotorasib group. The reasons for this non-evaluation was the non-realization of a tumour evaluation before the end of the study or initiation of an anti-cancerrous treatment. Sensitivity analyses to account for cross-over have shown similar results. Secondary judgement criteria without alpha risk management These criteria, which are purely exploratory and do not take into account the multiplicity of analyses, will not be presented.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Study population",
        "start_page": 10,
        "end_page": 13,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "As no statistically significant differences were shown in terms of glo-bal survival, the hierarchical sequence was therefore stopped and the quality of life criteria were not tested. The quality of life of patients was analysed using the QLQ-C30 and QLQ-LC13 questionnaire. However, given the following limitations: - Open study, - Hierarchical analysis interrupted upstream, No formal conclusions can be drawn from the quality of life results, which will not be presented.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Quality of life",
        "start_page": 13,
        "end_page": 13,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "3.3.1 Summary of the clinical data previously examined in the Commission's study (notice of 15/06/2022): study CodeBreak 100 (non-comparative basketball study) \"Tolerance data from the CodeBreak 100 study are derived from the data freeze of 15 March 2021, allowing for the greatest decline. The safety population was 126 patients, with a median duration of treatment of 24 weeks (min-max: 1-77). Almost all patients reported an adverse event (AE) (99%). The proportion of AEs of grades ≥ 3 was 61%, that of serious AEs of 55%, that of AEs leading to discontinuation of therapy of 9%, and that of AEs evolving towards death of 16%. Events of special interest were reported in 39% of patients were reported in the group of patients. The proportion of IEs leading to a temporary interruption of the drug was 28% in the docetaxel group and 51% in the sotorasib group. The proportion of IEs leading to a dose reduction of the drug was 29% in the docetaxel group and 15% in the sotorasib group. The proportion of IEs leading to death was 12% in the docetaxel group and 22% in the sotorasib group.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Tolerance profile",
        "start_page": 13,
        "end_page": 14,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following IEs of interest were collected using the sototaxel procedure (standardized MedDRA query) of the MedDRA dictionary (only the results of the so-called broad research are reported): - Hepatotoxicity: 9% in the docetaxel group (of which 1% grade ≥3), and 27% in the sotorasib group (of which 20% grade ≥3) − Pneumonia: 3% in the docetaxel group (of which 3% grade ≥3), and 2% in the so-torasib group (of which 1% grade ≥ 3% grade and 2% grade ≥ 3), including the docetaxe in the docetaxe group (of which 12% grade) and 2% grade",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Tolerance profile",
        "start_page": 13,
        "end_page": 14,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The risk summary of the LUMYKRAS RMP (sotorasib) (version 1.0 dated 15/11/2022) did not indicate any significant risk, potential risk or missing information.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Data from the RMP",
        "start_page": 14,
        "end_page": 14,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Periodic Benefit-Risk Evaluation Report (PBRR)/Periodic Safety Update Report (PSUR) covering the period from 28/11/2021 to 27/05/2022 was provided in support of this re-evaluation. No signal was closed during this period.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Data from PBRER/PSUR",
        "start_page": 14,
        "end_page": 14,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the case of patients who have not been treated, the total number of patients who have been treated has been reduced by only 47. Of the 440 accepted applications, 414 patients were considered treated (median provided by the laboratory). Of these, 403 patients were considered to be exposed to the so-torasib (11 patients who had never initiated treatment). The 414 patients considered to have been treated are described in the follow-up to this paragraph. Only 47 patients had a first documented follow-up visit. Given the insufficiency precision associated with this low number of patients, and the possibility of bias, the accepted follow-up data (effectiveness or tolerance) were considered to be accepted.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "3.4.1 Cohort ATU",
        "start_page": 14,
        "end_page": 15,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In total, these new data are not likely to provide robust evidence to assess the efficacy and safety of sotorasib. 3.4.2 1st post-AMM Early Access Report The laboratory provided data from the 1st early access follow-up report covering the period from 07/06/2022 to 07/02/23. Patients treated under early access could be patients already treated under the ATU of a cohort tipping into the early access system, or patients included directly in early access (depending on the date of patient inclusion).",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "3.4.1 Cohort ATU",
        "start_page": 14,
        "end_page": 15,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This retrospective observational study was intended to include patients with stage IV NSCLC with KRAS G12C mutation, who received at least one dose of sotorasib under ATU. The main objective was to assess survival without \"real-life\" progression. A total of 106 patients who started treatment with sotorasib between 15/03/2021 and 15/04/2022 were included in this study. It should be noted that these patients have already been included in the cohort ATU description (paragraph 3.4.1). These 106 patients represent 10% of the 1,011 patients treated under ATU. Given the insufficient accuracy associated with this low number, and the possibility of selection bias, these data are not likely to provide an unbiased estimate of efficacy and tolerance results in the ATU population.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "3.4.3 Observational study IFCT-2102 Lung KG12Ci",
        "start_page": 15,
        "end_page": 15,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Therefore, these data will not be described.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "3.4.3 Observational study IFCT-2102 Lung KG12Ci",
        "start_page": 15,
        "end_page": 15,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Study Name Study Diagram Data Availability Study CodeBreak Phase II, multicentre, open-label dose comparison study May 2026 100 (NCT03600883) (240 mg vs 960 mg) in patients with KRAS G12C muta- tion who have received at least one prior systemic treatment",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Programme of study",
        "start_page": 16,
        "end_page": 16,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This notice concerns the re-evaluation of LUMYKRAS (sotorasib) in its monotherapy indication in the treatment of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line. As a reminder, the initial assessment of LUMYKRAS (sotorasib) was based primarily on the CodeBreak 100 phase \"basket\" study. This non-comparative study was carried out in 224 patients, 126 of whom had an NSCBC. The main objective was to estimate the objective response rate, evaluated by an independent committee. The laboratory had also submitted indirect comparison data. Taking into account the major methodological limitations of these latter, the laboratory was also able to draw a formal conclusion on the basis of this non-comparisonal data, while clinically relevant comparators were available. These additional data are not likely to provide robust evidence to assess the efficacy and tolerance of sotorasib, particularly as a result of a significant proportion of missing data.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Discussion",
        "start_page": 16,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Therefore, no formal conclusion can be drawn. In total, LUMYKRAS (sotorasib) demonstrated its superiority over docetaxel in a randomised, open-label study (CodeBreak 200) conducted in 345 patients with a CBNPC with muta- tion KRAS G12C who received at least platinum-based chemotherapy and immunotherapy: - In terms of progression-free survival evaluated by an independent rereading committee according to the RECIST criteria 1.1: HR=0.66 [IC95%: 0.51-0.86] (p=0.095) (p=0.095) (immediate survival without progression according to the independent rereading committee was 5.6 months (min-max: 0-16.3) in the sotorasib group, and 4.5 months (min-max: 0-21.6) (immediate deviation: 0.09 However, the scope of these results is limited by the following points: - Despite the statistical significance, the point estimate of the absolute difference in progression-free survival is low, and the clinical relevance of this difference is questionable; - The open-label conduct of the study, resulting in possible evaluation biases, and in particular the evaluation of treatment decisions, with a significant increase in the docetaxel group of treatment changes before progression compared to the docetaxel group (31 patients versus 24); - The contradiction in the results of the intermediate progression-free survival analysis calls into question the reproducibility of this measure in this trial; - In a context of disease in the advanced stage, with an unfavourable short-term prognosis, the absence of demonstrated impact of LUMYKRAS (sotorasib) on overall survival, during the final analysis; - The lack of clinical relevance of the objective response rate in this context, taking into account in particular the availability of the final results of the overall survival analysis; - The absence of evidence of an adverse effect of LUMYKRAS (determinable) on the biodeterminability of the biodetermin nature of the biodeb.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Discussion",
        "start_page": 16,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Considering all this information and after debate and vote, the Commission considers that within the scope of the assessment:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Conclusions of the Commission on Transparency",
        "start_page": 17,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "LUMYKRAS (sotorasib) is a treatment option in the management of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Place of the drug in the therapeutic strategy",
        "start_page": 17,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In view of the current management (paragraph 2.2) and the place of the medicinal product in the therapeutic strategy (paragraph 5.1), the CCPs are the treatments mentioned in paragraph 2.2.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Clinically relevant comparators",
        "start_page": 17,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "(i) the risk of a disease being caused by a disease; (ii) the risk of a disease being caused by the disease; (iii) the risk of a disease being caused by the disease; (iv) the risk of a disease being caused by the disease; (v) the risk of a risk a risk a risk of a risk a risk",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Medical Service Rendu",
        "start_page": 18,
        "end_page": 18,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "LUMYKRAS (sotorasib) has shown statistically significant superiority in terms of progression-free survival and objective response rates evaluated by an independent review committee in an open-label randomised phase 3 study compared to docetaxel. However, this result is limited by: - the lack of clinical relevance of the absolute difference in median survival without progression, of about 1 month; - the open-label conduct of the study, which has led to possible biases in assessment, in particular in terms of treatment decisions; - the uncertain reproducibility of the measure of progression-free survival in this study; - the absence of evidence of an effect on overall survival, in an advanced stage with an unfavourable prognosis; - the lack of clinical relevance of the objective response rate in this con − the absence of a formal conclusion that can be drawn from the quality results − the safety profile of sotorasib, not appearing as more favorab cetaxel; the Commission considers that LUMYKRAS (sotorasib) does not make a medical contribution (sotorasib).",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Improvement of the Medical Service Rendu",
        "start_page": 18,
        "end_page": 19,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Commission considers that no data are likely to change the target estima achieved in the initial opinion.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Target population",
        "start_page": 19,
        "end_page": 19,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Not applicable.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Data request",
        "start_page": 19,
        "end_page": 19,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "It is adapted to the conditions of prescription according to the indication, dosage and the LUMYKRAS 120 mg, 19 July 2023 All our publications are downloadable on text-based disease text; can only be used to improve the service of the treatment population. te lliu j tn a s e d tiro tu A e tu a H",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "Other recommendations of the Commission",
        "start_page": 19,
        "end_page": 19,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1 : - Lung cancer - Row 2 : - Adult - Row 3 : - Sectors : City and Hospital",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading (ISP)",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n!",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading (ISP)",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nThis specialty is not likely to have an additional impact onRow 2:\nPublic health",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading (ISP)",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1 : - lack of evidence of an effect on overall survival, in the context of Row 2 : - lack of a formal conclusion that can be drawn from the quality results of Row 6 : - life;Row 7:\n- the safety profile of the sotorasib not appearing as more favourable thanRow 8:\n- the docetaxel;Row 9:\n- the Commission considers that LUMYKRAS (sotorasib) does not bring d'améliora--Row 10:\n- treatment of the medical service rendered (ASMR V) in relation to docetaxel. -Row 11:\nThe target population is estimated to be about 1950 patients.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading The target population is estimated at about 1950 patients.",
        "start_page": 2,
        "end_page": 2,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row: 1!Currency Framework for: ATC Code for: ADC for: ADC Code for: ADC ADC for: ADC for: ADC Code for: ACD for: ADC ADC ADC ADC ADC for: ACD for: ACD for: ACD for: ADC ADC ADC ADC ADC for: ADC for: ADC ADC ADC ADC A",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nDCI (ATC code)Row 2:\nPresentationsRow 3:\nconcerned*",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nLists) concerning-Row 2:\nborn(s)",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nConditions and sta-Row 2:\ntuts",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1 : , , ,",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 1)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nProcessRow 2:\nisRow 3:\n Row 4:\n Row 5:\node ARow 6:\nntationRow 7:\nBornRow 8:\n Row 9:\nconcRow 10:\n Row 11:\n Row 12:\nandoireRow 13:\nion cRow 14:\nr l ́évRow 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\nionsRow 20:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 2)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\neduraRow 2:\n Row 3:\n Row 4:\n Row 5:\nATC)Row 6:\nnsRow 7:\ns*Row 8:\n Row 9:\ncer-Row 10:\n Row 11:\n Row 12:\neRow 13:\nconceRow 14:\nvalua-Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\nand staRow 20:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 3)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nal-al-RévaluationRow 2:\n--Row 3:\n--",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\n Row 2:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1 : -sotorasib (L01XX73) - Row 2 : -LUMYKRAS 120 mg film-coated tablet - Row 3 : - 30 blisters PVC polyethylene PVDC aluminium 8: - Row 4 : - tablets (CIP 34009 302 419 3 6)",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 2:\ner-",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nInitial date: 06/01/2022 (centralised procedure):",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\na-",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Summary (from previous page, column 4)",
        "start_page": 4,
        "end_page": 4,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nsh",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading  General about the disease or condition concerned",
        "start_page": 5,
        "end_page": 5,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nEva-Row 2:\nPre-Row 3:\nTeeth",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading  General about the disease or condition concerned",
        "start_page": 5,
        "end_page": 5,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nEvaluation byRow 2:\nCommission",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading  General about the disease or condition concerned",
        "start_page": 5,
        "end_page": 5,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nNOM (INN) & Indication of AMM & Indication Date of AMM & Indication of AMM & Ind.",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading  Drug Treatments",
        "start_page": 6,
        "end_page": 6,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nCBNPC-NA-NA-NA-NA-Row 2:\nIn combination with cisplatin, in CBNPC for which po-tentially curative surgery and/or radiotherapy is not indicated, in combination with cisplatin, in CBNPC non-resectable, locally advanced or metastatic, in patients who have not received previous chemotherapy-rapy, in combination with cisplatin, in CBNPC non-resectable, locally advanced or metastatic, in patients who have not received previous chemotherapy, 21/07/2004 (registration)",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Immunotherapy",
        "start_page": 7,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nLocally advanced or metastatic CBNPC monotherapy after prior chemotherapy",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Immunotherapy",
        "start_page": 7,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nCBNPCRow 2:\nIn combination with cisplatin, in CBNPC for which po-tentially curative surgery and/or radiotherapy is not indicatedRow 3:\nIn combination with cisplatin, in non-resectable CBNPC, locally advanced or metastatic, in patients who have not received anterior chemotherapyRow 4:\nSecond-line CBNPC monotherapy, when histology is not predominantly epidermoid",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Immunotherapy (column 1)",
        "start_page": 7,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nMonotherapy in local advanced or metastatic CBNPC after prior chemotherapyRow 2:\nlocally advanced or metastatic epidermoid CBNPC after previous chemotherapyRow 3:\nlocally advanced or metastatic non-squad CBNPC after previous chemotherapy",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Immunotherapy (column 1)",
        "start_page": 7,
        "end_page": 7,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:\nName of the study:Schedule of the study:Availability of the Row:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading Discussion",
        "start_page": 16,
        "end_page": 16,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1 : In view of all this information and after debate and vote, the Commission considers that within the scope of the evaluation:",
      "metadata": {
        "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
        "heading": "table heading  Clinically relevant compares",
        "start_page": 17,
        "end_page": 17,
        "created_date": "2023",
        "country": "FR",
        "source_type": "hta_submission",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/FR/CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189_cleaned.json",
        "split_index": 0
      }
    }
  ]
}